The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Human LRCOL1 (Ensembl ENSG00000204583) encodes leucine rich colipase like 1, which UniProt describes as a precursor protein with a colipase/colipase-like domain (per the user-provided UniProt entry context) and is therefore hypothesized to be an extracellular/secreted accessory protein that could modulate lipase activity by analogy to canonical colipases; however, the retrieved citable literature and database evidence do not currently provide direct biochemical, cellular-localization, or pathway-level experimental characterization of LRCOL1 itself. The strongest citable evidence available in this run is (i) identity confirmation and (ii) hypothesis-generating disease/phenotype associations aggregated by the Open Targets Platform from heterogeneous datasets (RNA expression in liver tumor vs non-tumor tissue; a neuronal CRISPRi screen; and GWAS credible-set associations). (OpenTargets Search: -LRCOL1)
Verified target: Open Targets lists a human gene with approvedSymbol: LRCOL1 and approvedName: leucine rich colipase like 1, with stable gene identifier ENSG00000204583, consistent with the requested human gene/protein target. (OpenTargets Search: -LRCOL1)
Ambiguity check: In the sources retrieved in this run, there was no competing “LRCOL1” gene from another organism or an unrelated human gene with the same symbol; the principal challenge is instead that direct, LRCOL1-focused experimental literature is sparse. (OpenTargets Search: -LRCOL1)
“Colipase” classically refers to small secreted cofactors that bind pancreatic lipase and lipid interfaces to relieve bile-salt inhibition and facilitate triglyceride hydrolysis (general biochemical concept). In the present evidence set, the only citable statement relevant to this concept is that Open Targets confirms the gene name “leucine rich colipase like 1,” which implies a domain-driven naming convention rather than a demonstrated activity. (OpenTargets Search: -LRCOL1)
In UniProt usage, “precursor” typically denotes a protein with an N-terminal signal peptide and/or propeptide that is processed during secretion or maturation. In this tool run, no citable primary text was retrieved that confirms signal peptide presence or extracellular localization for LRCOL1, so this remains an inference anchored to the user-provided UniProt description rather than tool-retrieved evidence. (OpenTargets Search: -LRCOL1)
Direct evidence: None retrieved that defines an enzymatic reaction, substrate specificity, binding partners, or a validated molecular role for LRCOL1. (OpenTargets Search: -LRCOL1)
Best-supported functional hypothesis (domain-based): Because the requested UniProt entry indicates a colipase/colipase-like domain, the most plausible primary function is lipase cofactor-like activity (e.g., assisting lipid digestion or lipase function at lipid–water interfaces). This is a bioinformatic/domain-based inference and should be treated as unvalidated for LRCOL1 until targeted biochemical assays are reported. (OpenTargets Search: -LRCOL1)
Open Targets surfaces one functional genomics evidence item relevant to neuronal biology: a genome-wide CRISPRi screen in glutamatergic neurons (study label: “Glutamatergic Neuron-No Antioxidants-Survival-CRISPRi”; PMID 34031600) is included as an “affected pathway/functional” evidence source contributing to Open Targets’ association signals for neurodegenerative disease and other traits. This suggests LRCOL1 may have a measurable phenotype in at least one neuronal survival/stress paradigm, but does not specify a biochemical pathway. (OpenTargets Search: -LRCOL1)
No direct localization evidence (microscopy, secretion assays, proteomic compartment mapping) was retrieved in this run. (OpenTargets Search: -LRCOL1)
Within the constraints of the retrieved, citeable evidence, the most “recent” actionable items are not LRCOL1-focused mechanistic papers but rather integrated target–disease association resources and the appearance of relevant PMIDs in those resources:
Because the Open Targets excerpt does not provide publication years for each PMID in-line, this run cannot reliably assert which of these PMIDs are 2023–2024 without importing external bibliographic metadata. Therefore, recent (2023–2024) mechanistic developments specific to LRCOL1 could not be confirmed from retrieved evidence. (OpenTargets Search: -LRCOL1)
A clinical-trials search did not yield any citeable trial record tied to LRCOL1 in this run (the tool state indicates a trial count but no citeable trial context was returned). Therefore, no clinical implementation (intervention target, enrollment, endpoints) can be supported here. (tool output contained no citeable clinical-trial context IDs)
Open Targets’ incorporation of tumor vs adjacent tissue RNA-expression evidence (PMID 23766440) makes LRCOL1 a candidate biomarker hypothesis in hepatocellular carcinoma contexts, but the Open Targets record explicitly labels the confidence as low and provides no assay performance metrics (AUC, sensitivity/specificity) in the retrieved excerpt. (OpenTargets Search: -LRCOL1)
No relevant patents were retrieved for the queries used in this run. (tool output contained no citeable patent context IDs)
The most authoritative synthesis retrieved in this run is the Open Targets Platform integration itself, which aggregates multiple evidence modalities to support hypothesis building in drug discovery, and emphasizes that associations may be limited or absent when evidence is sparse. In this case, the Open Targets excerpt indicates only three evidence items tied to LRCOL1 in the retrieved record, consistent with a minimally characterized target. (OpenTargets Search: -LRCOL1)
From Open Targets’ association summaries for LRCOL1:
These scores are platform-specific composite metrics and should be interpreted comparatively (within Open Targets) rather than as direct effect sizes.
| Category | Item | Details | Source/URL |
|---|---|---|---|
| Verified identifier | Gene symbol | LRCOL1; approved name: leucine rich colipase like 1; human target corresponds to ENSG00000204583 in Open Targets, matching the requested human gene identity (OpenTargets Search: -LRCOL1) | Open Targets target record: https://platform.opentargets.org/target/ENSG00000204583 |
| Verified identifier | UniProt accession | A6NCL2; protein described in the prompt as the human UniProt entry for LRCOL1. This identifier is consistent with the requested target, but no separate citeable UniProt context ID was retrieved in-tool, so this row reflects verified conversation context plus Open Targets gene match (OpenTargets Search: -LRCOL1) | UniProt entry URL: https://www.uniprot.org/uniprotkb/A6NCL2/entry |
| Protein annotation | Recommended protein name | Leucine-rich colipase-like protein 1; annotated as precursor in the prompt. The name is concordant with Open Targets approved target name and the user-provided UniProt description (OpenTargets Search: -LRCOL1) | UniProt entry URL: https://www.uniprot.org/uniprotkb/A6NCL2/entry |
| Domain/family annotation | Domain architecture | User-provided UniProt/domain context indicates Colipase domain annotation (InterPro: IPR001981) and Colipase-like family/domain (Pfam: PF15083). Retrieved literature on remote homology notes PF15083 matches colipases, supporting colipase-like assignment at the family level, but not LRCOL1-specific function (OpenTargets Search: -LRCOL1) | InterPro: https://www.ebi.ac.uk/interpro/entry/InterPro/IPR001981 ; Pfam: https://pfam.xfam.org/family/PF15083 |
| Disease-association evidence | Hepatocellular carcinoma | Open Targets overall association score 0.05168. Evidence includes RNA expression from Expression Atlas study E-GEOD-33294 comparing liver tumor vs adjacent non-tumor tissue; PMID 23766440; confidence noted as low (OpenTargets Search: -LRCOL1) | Open Targets disease view: https://platform.opentargets.org/disease/EFO_0000182/associations |
| Disease-association evidence | Atrial fibrillation | Open Targets overall association score 0.18443. Supporting evidence list includes genetic association from GWAS credible sets; PMID 40645996 appears in the retrieved evidence summary (OpenTargets Search: -LRCOL1) | Open Targets disease view: https://platform.opentargets.org/disease/EFO_0000275/associations |
| Disease-association evidence | Brain aneurysm | Open Targets overall association score 0.14535. Supporting evidence list includes genetic association from GWAS credible sets; PMID 40645996 in retrieved evidence summary (OpenTargets Search: -LRCOL1) | Open Targets disease view: https://platform.opentargets.org/disease/EFO_0003870/associations |
| Disease-association evidence | Neurodegenerative disease | Open Targets overall association score 0.27186. Supporting evidence includes affected pathway / functional evidence from CRISPRi screen Glutamatergic Neuron-No Antioxidants-Survival-CRISPRi; PMID 34031600 (OpenTargets Search: -LRCOL1) | Open Targets disease view: https://platform.opentargets.org/disease/EFO_0005772/associations |
| Disease-association evidence | COVID-19 | Open Targets overall association score 0.02442. Supporting evidence list includes genetic association from GWAS credible sets; PMID 40645996 in retrieved evidence summary (OpenTargets Search: -LRCOL1) | Open Targets disease view: https://platform.opentargets.org/disease/MONDO_0100096/associations |
| Evidence inventory | Number and type of retrieved Open Targets evidence items | Retrieved Open Targets summary lists 3 evidence items tied to LRCOL1: (1) Expression Atlas RNA expression (PMID 23766440; study E-GEOD-33294), (2) CRISPRi functional/affected-pathway evidence (PMID 34031600; study Glutamatergic Neuron-No Antioxidants-Survival-CRISPRi), and (3) GWAS credible-set genetic association (PMID 40645996) (OpenTargets Search: -LRCOL1) | Open Targets target page: https://platform.opentargets.org/target/ENSG00000204583 |
| Limitation note | Sparse LRCOL1-specific literature | Tool searches found no direct primary papers focused specifically on human LRCOL1/A6NCL2 molecular function. Available evidence is mostly indirect, high-throughput, or database-integrated rather than targeted biochemical characterization (OpenTargets Search: -LRCOL1) | Open Targets target page: https://platform.opentargets.org/target/ENSG00000204583 |
| Limitation note | Function/localization uncertainty | Retrieved citeable evidence does not directly establish substrate, catalytic activity, pathway membership, or subcellular/extracellular localization for human LRCOL1. Colipase-like/domain-based inference is plausible but remains unvalidated by LRCOL1-specific functional experiments in the retrieved sources (OpenTargets Search: -LRCOL1) | Open Targets target page: https://platform.opentargets.org/target/ENSG00000204583 |
| Limitation note | Caution on disease links | Open Targets scores are small to modest and derive from heterogeneous evidence types; they should be interpreted as hypothesis-generating associations, not proof that LRCOL1 is causal or clinically actionable in these diseases (OpenTargets Search: -LRCOL1) | Open Targets documentation hub: https://platform-docs.opentargets.org/ |
Table: This table verifies the requested human LRCOL1 target identity and summarizes the currently retrievable evidence landscape. It is useful because it separates firm identifier/domain facts from much weaker, mostly indirect disease-association evidence and highlights the major evidence gaps.
Note on completeness: This report is necessarily limited by the evidence retrieved in-tool, which did not include LRCOL1-focused biochemical or cell biology studies, nor any UniProt/InterPro pages as citeable tool contexts. The strongest citable content available here is Open Targets’ integrated evidence listing and its associated PMIDs and association scores. (OpenTargets Search: -LRCOL1)
References